

**Form603**Corporations Act 2001  
Section 671B**Notice of initial substantial holder**

To Company Name/Scheme Little Green Pharma Ltd

ACN/ARSN 615 586 215

**1. Details of substantial holder (1)**

Name Elixer Ltd

ACN/ARSN (if applicable) N/A: TSX - V (Canada)

The holder became a substantial holder on 19/12/2017

**2. Details of voting power**

The total number of votes attached to all the voting shares in the company or voting interests in the scheme that the substantial holder or an associate (2) had a relevant interest (3) in on the date the substantial holder became a substantial holder are as follows:

Class of securities (4)	Number of securities	Person's votes (5)	Voting power(6)
Ordinary Shares	30,826,533	30,826,533	23.09%

**3. Details of relevant interests**

The nature of the relevant interest the substantial holder or an associate had in the following voting securities on the date the substantial holder became a substantial holder are as follows:

Holder of relevant interest	Nature of relevant interest (7)	Class and number of securities
Elixer Ltd	Relevant interest pursuant to section 608(1)(a) of the Corporations Act, being the registered holder of the securities.	30,826,533 fully paid ordinary shares

**4. Details of present registered holders**

The persons registered as holders of the securities referred to in paragraph 3 above are as follows:

Holder of relevant interest	Registered holder of securities	Person entitled to be registered as holder (8)	Class and number of securities
Elixer Ltd	Elixer Ltd	Elixer Ltd	fully paid ordinary shares

**5. Consideration**

The consideration paid for each relevant interest referred to in paragraph 3 above, and acquired in the four months prior to the date that the substantial holder became a substantial holder is as follows:

Holder of relevant interest	Date of acquisition	Consideration (9)		Class and number of securities
		Cash	Non-cash	
Elixer Ltd (was LGC Capital)	19 December 2017	\$1,500,000	\$635,435	7,500,000
Elixer Ltd (was LGC Capital)	16 February 2018		\$2,657,950	2,283,495
Elixer Ltd (was LGC Capital)	22 May 2019	\$5,500,000		18,350,000
Elixer Ltd (was LGC Capital)	2 August 2019	\$800,000		2,693,038

## 6. Associates

The reasons the persons named in paragraph 3 above are associates of the substantial holder are as follows:

Name and ACN/ARSN (if applicable)	Nature of association
N/A	N/A

## 7. Addresses

The addresses of persons named in this form are as follows:

Name	Address
Elixer Ltd	800 Place Victoria, Suite 3700, Montreal, QC, Canada

**Signature**

print name: Mazen Haddad

capacity

sign here



date 24/2/20

## DIRECTIONS

- (1) If there are a number of substantial holders with a similar or related relevant interest (e.g. a corporation and its related corporation or the manager and trustee of an equity trust), the names could be included in an annexure to the form. If the relevant interests of a group of persons are essentially similar, they may be referred to throughout the form as a specifically named group if the membership of each group, with the names of members is clearly set out in paragraph 7 of the form.
- (2) See the definition of 'associate' in section 9 of the Corporations Act 2001.
- (3) See the definition of 'relevant interest' in sections 608 and 671B (7) of the Corporations Act 2001.
- (4) The voting shares of a company constitute one class unless divided into separate classes.
- (5) The total number of votes attached to all the voting shares in the company or voting interests in the scheme (if any) that the person or an associate has a relevant interest in.
- (6) The person's votes divided by the total votes in the body corporate or scheme multiplied by 100.
- (7) Include details of:
  - a) any relevant agreement or other circumstance by which the relevant interest was acquired. If subsection 671B(4) applies, a copy of any document setting out the terms of any relevant agreement, and a statement by the person giving full and accurate details of any contract, scheme of arrangement, must accompany this form, together with a written statement certifying this contract scheme or arrangement, and
  - b) an qualification of the power of a person to exercise, control the exercise of, or influence the exercise of, the voting powers or disposal of the securities to which the relevant interest relates indicating clearly the particular securities to which the qualification applies).
- (8) If the substantial holder is unable to determine the identity of the person (e.g. if the relevant interest arises because of an option) write 'unknown'.
- (9) Details of the consideration must include any and all benefits, money and other, that any person from whom a relevant interest was acquired has, or may, become entitled to receive in relation to that acquisition. Details must be included even if the benefit is conditional on the happening or not of a contingency. Details must be included of any benefit paid of the substantial holder or its associate in relation to the acquisitions, even if they are not paid directly to the person from whom the relevant interest was acquired.